CD4 and neoplasm: Moreover, treating CD4 T cells with concanamycin A (CMA), a well-established inhibitor of the perforin-dependent killing pathway26, resulted in reduced cytotoxicity of HT-29 tumor cells in vitro (Fig. 6E).